



**Company Contact:**

**Richard Gabriel**  
**President and CEO**  
**941-366-3400**

**-or-**

**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS TO PARTICIPATE IN PHARMACOGENOMICS E-SYMPOSIUM**

**SARASOTA, Fla., Dec. 8, 2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG)** announced today that the Company will participate in a live electronic symposium hosted by the International Society of Pharmacogenomics on Monday, December 12.

DNAPrint genomics Founder and Chief Scientific Officer Tony N. Frudakis will make a presentation about the role the Company's wholly owned DNAPrint Pharmaceuticals, Inc., subsidiary is playing in the development of personalized medicines utilizing human population genetics technology. He will focus on genomic-based pharmacogenomic test/drug combinations called "theranostics," which are designed to improve efficacy and reduce side effects by matching a patient with the most appropriate drug. Dr. Frudakis' portion of the webcast event, scheduled for 11:30 a.m. Eastern time, can be accessed at <http://www.pharmacogen.e-symposium.com>.

DNA Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., will participate in a panel discussion and roundtable focusing on the role pharmacogenomics has to play in treating cardiac patients. The Cardiovascular Pharmacogenomics roundtable is scheduled to start at 1:30 p.m. Eastern time and also can be accessed at <http://www.pharmacogen.e-symposium.com>.

"The Pharmacogenomics E-Symposium™ brings together officials, regulators and researchers from within the global pharmaceutical industry," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It is an excellent platform for providing broad industry exposure for DNAPrint Pharmaceuticals, Inc., our newly formed pharmaceutical subsidiary."

**About DNAPrint genomics, Inc.**

DNAPrint genomics, Inc. ([www.dnaint.com](http://www.dnaint.com)), through its DNAPrint Pharmaceuticals, Inc., wholly owned subsidiary, is a developer of genomics-based products and services focused on drug development, computational biology and pharmacogenomic diagnostic tests. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint also develops and markets products for the law enforcement forensics and consumer markets that include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which such statements are based.

###